SCHEMBL6448689

SCHEMBL6448689

NC(=S)c1ncccc1[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.50
POLB P06746 1/20 0.49
ALDH1A1 P00352 5/20 0.45
MAPT P10636 4/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
KDM4E B2RXH2 2/20 0.45
CTSB P07858 2/20 0.45
LMNA P02545 2/20 0.45
HSP90AA1 P07900 2/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C9 P11712 2/20 0.45
GAA P10253 1/20 0.45
IDO1 P14902 1/20 0.45
TDO2 P48775 1/20 0.45
NCOA1 Q15788 1/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8565503 0.86 PDE10A (0.50) PDE10APOLBALDH1A1MAPTMEN1
SCHEMBL6451146 0.84 PDE10A (0.49) PDE10APOLBALDH1A1MAPTMEN1
SCHEMBL305884 0.81 PDE10A (0.53) PDE10APOLBALDH1A1MAPTMEN1
SCHEMBL15208231 0.81 PDE10A (0.46) PDE10APOLBALDH1A1MAPTMEN1
SCHEMBL6451376 0.81 PDE10A (0.46) PDE10APOLBALDH1A1MAPTMEN1
SCHEMBL6451422 0.81 PDE10A (0.46) PDE10APOLBALDH1A1MAPTMEN1
SCHEMBL1232905 0.80 KDM4E (0.54) PDE10APOLBALDH1A1MAPTMEN1
SCHEMBL3381186 0.79 ALDH1A1 (0.51) PDE10APOLBALDH1A1MAPTMEN1
SCHEMBL28228342 0.79 PDE10A (0.50) PDE10APOLBALDH1A1MAPTMEN1
SCHEMBL24377212 0.78 CTSD (0.57) PDE10APOLBALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC PDE10A 3359/4885POLB 2806/4885ALDH1A1 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.